Thursday, July 31, 2025 7/31/2025

Genetic Control of the SYK Tyrosine-protein Kinase in Allergy

Award Number: R01AI181867
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/22/2024
PERIOD OF PERFORMANCE END DATE: 11/30/2028

Group Awards By:

View Award Description

Genetic Control of the SYK Tyrosine-protein Kinase in Allergy - SUMMARY Allergic diseases represent a major public health burden characterized as an epidemic that involves the interplay between genetic factors and environmental exposures. Allergens are one of the many multiple triggers that produce IgE and cause inflammation of the airways, two crucial components of allergic disorders, including atopic asthma. Spleen associated tyrosine kinase (aka tyrosine-protein kinase SYK) is critically involved in the earliest steps of signaling reaction following aggregation of IgE/FceRI on the basophil/mast cell surface after re-exposure to the same environmental substance (allergen). There is a considerable body of evidence and a consistent set of observations, based on cellular functions and clinical associations, highlighting the deeper relevance of SYK to the IgE-mediated reaction in humans. In addition, we have demonstrated that basophil traits, such as SYK expression and IgE-mediated histamine release, can serve as biomarkers for predicting the clinical efficacy of omalizumab in allergic diseases like asthma. However, little is known about the genetic regulation of SYK, which is crucial in determining how IgE-dependent allergy disorders manifest. We confirmed that the expression levels of SYK and histamine release in human basophils were correlated with single nucleotide polymorphisms (SNPs) in the promoter of the SYK gene. Exploration of cis-expression quantitative trait loci (cis-eQTL) discovered a genomic region encompassing the SYK transcription start site (TSS), and it contained multiple variants with a high potential for transcriptional regulation. We hypothesize that genetic factors interact with specific local cell/tissue environments to modify either SYK expression or its function; therefore defining a unique molecular phenotype of human basophils, which can serve as biomarkers for clinical efficacy of anti-IgE therapy as well as being potential drug targets for novel therapeutics. This application's specific aims are to: (1) determine the genetic regulation of SYK transcriptional activity and function; (2) identify common haplotypes that influence SYK expression and function in individuals of European and African ancestry; and (3) compare transcriptome gene signatures among IgE-bearing cell types. Results from these studies will provide strong motivation to explore the larger impact of their influences on atopic disorders.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $558,733 )
2025	2025	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	000	2	2/12/2025	NON-COMPETING CONTINUATION	$558,733
														Subtotal = $558,733

Issue Date FY: 2024 ( Subtotal = $576,014 )
2024	2024	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	001	1	9/4/2024	NEW	$57,601
2024	2024	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	000	1	1/22/2024	NEW	$518,413
														Subtotal = $576,014

Grand Total All Awards = $1,134,747

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Genetic Control of the SYK Tyrosine-protein Kinase in Allergy

Award Number: R01AI181867

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/22/2024

PERIOD OF PERFORMANCE END DATE: 11/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer